-> Lung cancer types

Integrative Cancer Science • Global Impact • Individualized Patient Care: Highlights of the AACR 2019 Annual Meeting

I have a huge soft spot for the annual AACR meeting. Back in my graduate school days, the annual AACR meeting was the largest global gathering of basic cancer researchers. With over 23,000 attendees this year, it still is—except that the meeting has evolved over the years to include more and more clinical research to answer the fundamental question: How can we truly build upon our knowledge of basic science to impact patient care? The 2019 annual meeting takes this question a step forward, as evident from this year’s meeting theme.

Webinar: Comprehensive Biomarker Testing in Advanced-Stage Lung Cancers

Since the discovery of the first epidermal growth factor receptor (EGFR) mutation in lung cancer in 2004, targeted therapies and immunotherapies have become a major component of the treatment arsenal for non-small cell lung cancer (NSCLC). Biomarkers are features of a cancer that predict how it will respond to certain treatments. They help doctors select the most appropriate treatment for the cancer.

Two examples of biomarkers are:

Webinar: Stage III Non-small Cell Lung Cancer and Immunotherapy

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising 85% of all diagnosed cases of lung cancer. Treatment of NSCLC is dependent on the stage of the disease, determined during the lung cancer staging process. In stage III NSCLC, the primary (original) tumor is large and the cancer has spread to lymph nodes in the center of the chest or other lymph nodes that are on the same side as the primary tumor.

New Technique Deepens Our Understanding of Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers and is found most often in people with a history of tobacco exposure. Patients with late-stage SCLC often respond so well to initial treatments that the cancer usually regresses and can even become undetectable in some cases. Unfortunately, in the vast majority of these cases, the cancer soon returns aggressively and is then resistant to treatment.

A Solid Step Toward the Early Detection of Squamous Cell Lung Cancer

Dr. Joshua Campbell has been immersed in the field of lung cancer for several years and wanted to find a better way to diagnose squamous cell lung cancer patients, a subtype of non-small cell lung cancer, while the cancer is in early stages. “There is a huge need for research in this area,” he notes. “Improving early detection techniques will be key to improving survival rates for patients with squamous cell lung cancer.”

Hope on the Horizon for KRAS-positive Lung Cancer Patients

A newly diagnosed patient with advanced-stage adenocarcinoma, a sub-type of non-small cell lung cancer (NSCLC), may have their biopsy tissue tested for known biomarkers. The oncologist requests biomarker testing to look for changes in cancer cells to help personalize the patient’s treatment. Patients that are positive for biomarkers such as PD-L1 and EGFR have seen a lot of progress in treatment options over the last five years. However, targeted treatments for the KRAS mutation haven’t yet arrived.

Driving Innovative Cancer Science to Patient Care―Highlights of AACR 2018

Driving Innovative Cancer Science to Patient Care was the name of this year’s April meeting of the American Association for Cancer Research (AACR) in Chicago, and it was fitting―there were lots of exciting advances in targeted therapies, immunotherapy, and more that I am pleased to share with you in this blog.

Targeted Therapies

Progress in targeted therapies is continuing in two areas.